Alzheimer's disease, Alzheimer’s, Artificial Intelligence, Big Data, category-/Health/Aging & Geriatrics, category-/Health/Health Conditions/Neurological Conditions, category-/Health/Health Foundations & Medical Research, dementia, Dev, machine learning, Pfizer

IBM and Pfizer claim AI can predict Alzheimer’s onset with 71% accuracy

IBM and Pfizer claim to have developed a model that can predict the onset of Alzheimer’s disease years before clear symptoms develop.

aducanumab, Alzheimer’s, Analyst Color, Analyst Ratings, Benzinga, BIIB, Biotech, ESALY, fda, Marc Goodman, Movers, News, SVB Leerink, Top stories, Trading Ideas, US09062X1037

Biogen Soars As FDA Accepts Alzheimer’s Drug For Review In ‘Next Stage Of Aducanumab Saga’

Biogen Inc’s (NASDAQ: BIIB) investigational Alzheimer’s drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day.

Latest Ratings for BIIB
DateFirmActionFromTo Jul 2020Morgan StanleyU…